Emerging treatments
B-cell depleting agents and other novel agents
Emerging treatments that may be suitable for IgAV are based on targeting mucosal immunity (e.g., tonsillectomy), B- or T-cell modulation (e.g., belimumab, telitacicept), endothelin (e.g., sparsentan), specific cytokine targets (e.g., interleukin-2), complement pathway regulation (e.g., avacopan, iptacopan), and other immunomodulatory treatments.[49] Despite these potential targets, there remains very few open clinical trials. The use of B-cell depleting agents (e.g., ofatumumab, bortezomib) and other novel biologic agents has been reported in patients with refractory IgAV nephritis.[49]
Use of this content is subject to our disclaimer